<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04667871</url>
  </required_header>
  <id_info>
    <org_study_id>XZZ-meibomian gland</org_study_id>
    <nct_id>NCT04667871</nct_id>
  </id_info>
  <brief_title>Effect of Cataract Hyperemulsification Surgery on Meibomian Gland Morphology and Function</brief_title>
  <official_title>Effect of Cataract Hyperemulsification Surgery on Meibomian Gland Morphology and Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yune Zhao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wenzhou Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      50 participants at Eye Hospital of Wenzhou Medical University during August, 2017 to July,&#xD;
      2020 will be enrolled in this study. To study the effect of cataract supermammary surgery on&#xD;
      the morphology and function of meibomian glands&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    An six-month follow-up was completed after the treatment&#xD;
  </why_stopped>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Actual">September 1, 2020</completion_date>
  <primary_completion_date type="Actual">July 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>OSDI scale survey</measure>
    <time_frame>08/2017 to 07/2020</time_frame>
    <description>OSDI scale survey</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tear meniscus height（mm）</measure>
    <time_frame>08/2017 to 07/2020</time_frame>
    <description>tear meniscus height（mm）</description>
  </primary_outcome>
  <primary_outcome>
    <measure>first tear film rupture time（s）</measure>
    <time_frame>08/2017 to 07/2020</time_frame>
    <description>first tear film rupture time（s）</description>
  </primary_outcome>
  <primary_outcome>
    <measure>average tear film rupture time（s）</measure>
    <time_frame>08/2017 to 07/2020</time_frame>
    <description>average tear film rupture time（s）</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the range of meibomian gland missing（%）</measure>
    <time_frame>08/2017 to 07/2020</time_frame>
    <description>the range of meibomian gland missing（%）</description>
  </primary_outcome>
  <primary_outcome>
    <measure>meibomian gland average diameter (mm)</measure>
    <time_frame>08/2017 to 07/2020</time_frame>
    <description>meibomian gland average diameter (mm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>meibomian gland length (mm)</measure>
    <time_frame>08/2017 to 07/2020</time_frame>
    <description>meibomian gland length (mm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>meibomian gland area (mm^2)</measure>
    <time_frame>08/2017 to 07/2020</time_frame>
    <description>meibomian gland area (mm^2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>meibomian gland deformation coefficient</measure>
    <time_frame>08/2017 to 07/2020</time_frame>
    <description>meibomian gland deformation coefficient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>meibomian gland total proportion of glands (%)</measure>
    <time_frame>08/2017 to 07/2020</time_frame>
    <description>meibomian gland total proportion of glands (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>meibomian gland imaging value</measure>
    <time_frame>08/2017 to 07/2020</time_frame>
    <description>meibomian gland imaging value</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>Eyes for cataract surgery</arm_group_label>
    <description>Eyes for cataract surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eyes without cataract surgery</arm_group_label>
    <description>Eyes without cataract surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cataract surgery</intervention_name>
    <description>Eyes for cataract surgery</description>
    <arm_group_label>Eyes for cataract surgery</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Those patients who undergoing cataract hyperemulsification surgery and previously untreated&#xD;
        with xerophthalmia.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previously untreated patients with xerophthalmia&#xD;
&#xD;
          -  Undergoing cataract hyperemulsification surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No history of ocular surgery and trauma&#xD;
&#xD;
          -  Any eye diseases except xerophthalmia&#xD;
&#xD;
          -  No treated for xerophthalmia before&#xD;
&#xD;
          -  Successful completion of follow-ups&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>38 Years</minimum_age>
    <maximum_age>87 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 4, 2020</study_first_submitted>
  <study_first_submitted_qc>December 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>December 14, 2020</last_update_submitted>
  <last_update_submitted_qc>December 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Wenzhou Medical University</investigator_affiliation>
    <investigator_full_name>Yune Zhao</investigator_full_name>
    <investigator_title>Vice president of Eye Hospital of Wenzhou Medical University</investigator_title>
  </responsible_party>
  <keyword>meibomian gland</keyword>
  <keyword>cataract surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Meibomian Gland Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

